Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

被引：65
作者：
Berraondo, Pedro [1 ,2 ,3 ]
Etxeberria, Inaki [1 ,2 ]
Ponz-Sarvise, Mariano [2 ,4 ,5 ]
Melero, Ignacio [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Navarra, Ctr Appl Med Res CIMA, Immunol & Immunotherapy Program, Pamplona, Spain
[2] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain
[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[4] CUN, Dept Oncol, Pamplona, Spain
[5] CUN, Dept Immunol, Pamplona, Spain
来源：
CLINICAL CANCER RESEARCH | 2018年 / 24卷 / 12期
关键词：
T-CELL TRANSFER; DOXORUBICIN; THERAPY;
D O I：
10.1158/1078-0432.CCR-18-0381
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNg. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. (C) 2018 AACR.
引用
收藏
页码：2716 / 2718
页数：3
相关论文
共 11 条
  • [11] Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
    Zhang, Ling
    Morgan, Richard A.
    Beane, Joal D.
    Zheng, Zhili
    Dudley, Mark E.
    Kassim, Sadik H.
    Nahvi, Azam V.
    Ngo, Lien T.
    Sherry, Richard M.
    Phan, Giao Q.
    Hughes, Marybeth S.
    Kammula, Udai S.
    Feldman, Steven A.
    Toomey, Mary Ann
    Kerkar, Sid P.
    Restifo, Nicholas P.
    Yang, James C.
    Rosenberg, Steven A.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2278 - 2288
12